This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Constitutional short stature

Authoring team

Constitutional delay of growth and puberty may be diagnosed in short adolescents who have delayed puberty, a delayed bone age, and no underlying illness.

  • this a diagnosis of exclusion
  • this diagnosis has been associated with psychological difficulties and deviant behaviour
  • adults with constitutional delay of puberty and growth have a short spinal length compared to leg length
  • treatment with sex or anabolic steroids is an effective and safe treatment that achieves secondary sexual characteristics, but does not improve final height
  • it has been shown that oestrogen is the predominant hormone that leads to epiphyseal closure in both sexes. Aromatase inhibitors block the conversion of testosterone to oestrogen. Thus the combination of testosterone therapy and a specific aromatase inhibitor has potential as an effective treatment of constitutional pubertal delay in males. In this therapeutic option the testosterone provides a growth spurt and virilisation, while the aromatase inhibitor delays epiphyseal closure and thus allows growth over a longer period of time

Reference:

  • (1) Lancet (2001), 357 (9270), 1723-4

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.